Drugs.com - Clinical Trials

LimmaTech Awarded FDA Fast Track Designation for Vaccine Candidate Against Staphylococcus aureus

SCHLIEREN, Switzerland--(BUSINESS WIRE)-- December 19, 2024 LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the U.S. Food and Drug Administration...

Feb 9, 2025 - 21:44
 0
LimmaTech Awarded FDA Fast Track Designation for Vaccine Candidate Against Staphylococcus aureus
SCHLIEREN, Switzerland--(BUSINESS WIRE)-- December 19, 2024 LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the U.S. Food and Drug Administration...
Read More

Tags:

Previous Article

CagriSema Demonstrates Superior Weight Loss in Adults with Obesity or Overweight...

Next Article

Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of ...

Related Posts

Camizestrant Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in 1st-Line Advanced HR-Positive Breast Cancer with an Emergent ESR1 Tumor Mutation in SERENA-6 Phase III Trial

Camizestrant Demonstrated Highly Statistically Signific...

Feb 27, 2025  0

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of Qtorin 3.9% Rapamycin Anhydrous Gel (Qtorin rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old

Palvella Therapeutics to Expand Phase 3 SELVA Clinical ...

Feb 13, 2025  0

Arbor Biotechnologies Announces FDA Orphan Drug and Rare Pediatric Disease Designations Granted to ABO-101 for the Treatment of Primary Hyperoxaluria Type 1 (PH1)

Arbor Biotechnologies Announces FDA Orphan Drug and Rar...

Feb 9, 2025  0